Enicepatide

A weekly injection still in development. Enicepatide, CT-388 and RO7795068 name the same investigational peptide. It activates GLP-1 and GIP, two gut-hormone signals involved in appetite and blood sugar. It is a different molecule from tirzepatide, not an amylin drug or a three-target agonist. Roche enicepatide Phase II results in type 2 diabetes (Official context · Accessed 2026-09-30)

Enicepatide is an experimental weekly GLP-1/GIP peptide injection, also called CT-388. People following obesity drugs discuss it as a possible future alternative to tirzepatide. The useful community conversation concerns trial results, tolerability and access; the inspected posts do not establish a direct-use experience timeline.

A possible alternative, rather than an interchangeable shot. Zepbound discussions mention CT-388 when people look for future dual-hormone options. The comparison explains the interest; it does not mean an existing tirzepatide amount, benefit or side-effect pattern transfers to Enicepatide. Science people — What's next for GIP? (Community discussion · Accessed 2026-09-30)

Source context — Roche enicepatide Phase II results in type 2 diabetes: Sponsor topline release for CT388-104, distinct from obesity CT388-103. Full dose-group outcomes and individual diaries absent.

Source context — Science people — What's next for GIP?: Benefits described concern Zepbound; receptor percentages and anti-inflammatory explanations are user beliefs, not demonstrated enicepatide effects.

Looking for participants is not an outcome report. The CT-388 Roche post asks for people in Phase III to encourage one another. An investor-thread reply also seeks fellow participants. Neither supplies enough treatment detail to establish positive, unchanged or adverse Enicepatide experiences. CT-388 Roche (Community discussion · Accessed 2026-09-30) · Roche phase 2 CT-388 (Community discussion · Accessed 2026-09-30)

No dependable personal onset window. The checked posts do not establish when Enicepatide first changes hunger, food noise or digestion. Reports of quick effects from tirzepatide or another peptide cannot fill that gap, and a blood-concentration peak is a different measurement. CT-388 Roche (Community discussion · Accessed 2026-09-30)

More weight loss after progress slows. A patient-created GLP-1 Forum article focuses on continued loss without a plateau at the end of the obesity study. It also acknowledges that a curve still falling at 48 weeks does not establish endless weight loss or a lasting advantage. Roche CT-388 im Fokus: Ist das der lang ersehnte Durchbruch gegen das Abnehm-Plateau? (Community guide · Accessed 2026-09-30)

A treatment they can keep using. In r/Zepbound, one person losing insurance coverage wanted to retain the benefits they associated with GIP during maintenance, and a reply named CT-388. Those are reasons for interest, not Enicepatide evidence for inflammation, hormones or a cheaper prescription. Science people — What's next for GIP? (Community discussion · Accessed 2026-09-30)

Same results, different judgments. One r/NovoNordisk_Stock commenter saw roughly Zepbound-level performance; others were unimpressed or questioned manufacturing and time to market. Replies confused placebo-group loss with placebo-adjusted loss. That disagreement shows why a headline percentage alone is a poor drug ranking. Roche phase 2 CT-388 (Community discussion · Accessed 2026-09-30)

Source context — CT-388 Roche: Request for participant community, no dose, outcome or verified enrollment. Recommended posts excluded.

Source context — Roche phase 2 CT-388: Investor opinions and conflicting percentage interpretations; participant-seeking comment is not a diary.

Source context — Roche CT-388 im Fokus: Ist das der lang ersehnte Durchbruch gegen das Abnehm-Plateau?: Patient-created, AI-assisted analysis of sponsor data; not enicepatide self-use. Original author Mathias Köster; one source family, no independent trial evidence.

Source context — Science people — What's next for GIP?: Benefits described concern Zepbound; receptor percentages and anti-inflammatory explanations are user beliefs, not demonstrated enicepatide effects.

No established independent community dose range. The inspected participant-seeking posts give no amount or adjustment history. The frozen record warns against copying tirzepatide's 2.5–15 mg schedule. Milligrams describe the amount of each molecule, not a universal scale of potency. CT-388 Roche (Community discussion · Accessed 2026-09-30)

22 mg appears as an early-trial reference. A ProInvestor commenter repeats an early CT-388 trial amount while discussing why larger milligram amounts do not necessarily mean larger effects across drugs. It is secondhand trial information, not that commenter's weekly use or a consumer starting dose. Wegovy runder 100.000 danske aktive brugere (Secondhand community claim · Accessed 2026-09-30)

Target doses and study length. The obesity trial used 4, 8, 12, 16 and 24 mg beneath the skin once weekly for 48 weeks, with differing gradual increases. Early Phase I regimens were 0.5–7.5 mg once or 5–12 mg weekly for four doses. Roche investor event at ADA 2026 (Official context · Accessed 2026-09-30) · CT-388 EASD 2024 supplemental material — preserved measured values (Official context · Accessed 2026-09-30)

Source context — CT-388 Roche: Request for participant community, no dose, outcome or verified enrollment. Recommended posts excluded.

Source context — Wegovy runder 100.000 danske aktive brugere: Danish investor discussion, translated/paraphrased. Numbers repeat early trial information, not personal dosing. Date not exposed in inspected body; page repeats on /6 and shares one allowance.

Source context — Roche investor event at ADA 2026: Sponsor slides, same CT388-103 cohort as January release; no independent replication. Other compound slides excluded.

Source context — CT-388 EASD 2024 supplemental material — preserved measured values: PDF initial web extraction advertised 514 lines; subsequent text access failed, screenshot yielded no viewable image, direct retrieval returned HTTP 403. Exact measurements retained from previously reviewed frozen record, not freshly reverified. Cohort-specific human trial values.

No dependable personal onset window. The checked posts do not establish when Enicepatide first changes hunger, food noise or digestion. Reports of quick effects from tirzepatide or another peptide cannot fill that gap, and a blood-concentration peak is a different measurement. CT-388 Roche (Community discussion · Accessed 2026-09-30)

No established per-dose felt duration. A weekly study schedule does not show whether appetite effects stay even throughout a week. The preserved community record contains no missed-week diary from which to infer fading, rebound hunger or lingering benefit. CT-388 Roche (Community discussion · Accessed 2026-09-30)

Half-life is not a felt clock. Earlier Phase I reporting listed 134.6 hours at week 12 in the 8 mg group and 151.2 hours at week 24 in pooled 12/22 mg groups; median blood-peak time was 24 hours. CT-388 EASD 2024 supplemental material — preserved measured values (Official context · Accessed 2026-09-30)

Source context — CT-388 Roche: Request for participant community, no dose, outcome or verified enrollment. Recommended posts excluded.

Source context — CT-388 EASD 2024 supplemental material — preserved measured values: PDF initial web extraction advertised 514 lines; subsequent text access failed, screenshot yielded no viewable image, direct retrieval returned HTTP 403. Exact measurements retained from previously reviewed frozen record, not freshly reverified. Cohort-specific human trial values.

No supported community on/off calendar. People watching the pipeline discuss future maintenance options, not an Enicepatide course with a tested break and restart. Trial lengths and projected completion dates describe development; they do not specify a consumer cycle. Science people — What's next for GIP? (Community discussion · Accessed 2026-09-30) · A look at the competition (Community discussion · Accessed 2026-09-30)

Source context — Science people — What's next for GIP?: Benefits described concern Zepbound; receptor percentages and anti-inflammatory explanations are user beliefs, not demonstrated enicepatide effects.

Source context — A look at the competition: Registry dates copied by a user are not approval dates. Search version includes an unidentified trial report; it does not name enicepatide and is excluded. Opened and indexed versions differ.

Diabetes and combination work are separate. September diabetes topline results reported 15.5% loss at 48 weeks in the 24 mg arm. Zealand's pipeline anticipates a petrelintide combination trial in the second half of 2026; that is development, not an established user stack. Roche enicepatide Phase II results in type 2 diabetes (Official context · Accessed 2026-09-30) · Petrelintide / CT-388 pipeline (Official context · Accessed 2026-09-30)

Planned + petrelintide. [trial]

Comparison drugs: Tirzepatide, retatrutide and eloralintide appear as alternatives in discussion, not established enicepatide combinations. [community]

The preferred effect can matter more than the biggest loss. One r/tirzepatidecompound commenter hoped to try CT-388 after approval, while reporting disabling fatigue with cagrilintide and unwanted faster digestion with retatrutide. They planned to stay with tirzepatide meanwhile. These are experiences with other compounds explaining interest in Enicepatide, not Enicepatide adverse reports. A question I have not seen on this sub—How big are we? (Community discussion · Accessed 2026-09-30)

Source context — Roche enicepatide Phase II results in type 2 diabetes: Sponsor topline release for CT388-104, distinct from obesity CT388-103. Full dose-group outcomes and individual diaries absent.

Source context — Petrelintide / CT-388 pipeline: Commercial sponsor pipeline projection, not proof of an effective or safe user combination; updates old first-half/mid-2026 plans.

Source context — A question I have not seen on this sub—How big are we?: One user's experiences with other drugs and hoped-for CT-388 insurance coverage; no CT-388 use.

Digestive effects remain relevant. Roche reported mostly mild-to-moderate gastrointestinal events; obesity-trial treatment discontinuation due to adverse events was 5.9% across active arms versus 1.3% with placebo. These group results do not predict an individual's tolerability. Roche CT-388 obesity Phase II announcement (Official context · Accessed 2026-09-30)

A CT-388 vial label does not verify its contents. The original community caution distinguishes gray-market material from the sponsor's study product. It provides no validated preparation method or assurance of identity, purity or safety.

Worse-than-Zepbound claims are comparisons, not diaries. The frozen record preserves skeptical analyst sentiment about tolerability and arriving late. Without a direct comparison or a first-person timeline, that judgment cannot tell a reader how their own experience would differ. Roche phase 2 CT-388 (Community discussion · Accessed 2026-09-30)

The preferred effect can matter more than the biggest loss. One r/tirzepatidecompound commenter hoped to try CT-388 after approval, while reporting disabling fatigue with cagrilintide and unwanted faster digestion with retatrutide. They planned to stay with tirzepatide meanwhile. These are experiences with other compounds explaining interest in Enicepatide, not Enicepatide adverse reports. A question I have not seen on this sub—How big are we? (Community discussion · Accessed 2026-09-30)

Source context — Roche CT-388 obesity Phase II announcement: Sponsor announcement; promotional framing and estimands require qualification. Same source-origin family as reproduced release PDFs.

Source context — Roche phase 2 CT-388: Investor opinions and conflicting percentage interpretations; participant-seeking comment is not a diary.

Source context — A question I have not seen on this sub—How big are we?: One user's experiences with other drugs and hoped-for CT-388 insurance coverage; no CT-388 use.